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A  major  limitation  in  the  development  and  testing  of  new  tuberculosis  (TB)  vaccines  is  the  current  inade-
quate understanding  of  the  nature  of  the  immune  response  required  for  protection  against  either  infection
with Mycobacterium  tuberculosis  (MTB)  or progression  to disease.  Genome  wide  RNA  expression  analysis
has  provided  a new  tool  with  which  to  study  the  inﬂammatory  and  immunological  response  to  mycobac-
teria.  To  explore  how  currently  available  transcriptomic  data  might  be  used  to understand  the  basis  ofuberculosis
accines
nterferon-
ype I interferon
protective  immunity  to  MTB,  we  analysed  and  reviewed  published  RNA  expression  studies  to (1)  identify
a  “susceptible”  immune  response  in patients  with  acquired  defects  in the  interferon  gamma  pathway;  (2)
identify  the “failing”  transcriptomic  response  in  patients  with  TB  as compared  with  latent  TB infection
(LTBI);  and  (3)  identify  elements  of  the  “protective”  response  in  healthy  latently  infected  and  healthy
uninfected  individuals.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
The development of improved vaccines against Mycobacterium
uberculosis (MTB) is a high priority for the global effort to
educe the incidence of tuberculosis (TB) [1]. Although bacille
almette–Guerin (BCG) is one of the most widely used vaccines, and
s administered soon after birth in many high burden countries, the
accine has limited efﬁcacy in preventing pulmonary TB in adults
ith efﬁcacy ranging from 0 to 80% [2,3] and the duration of pro-
ection is unclear [4,5]. However BCG has largely been retained in
hildhood immunisation schedules because of its effect in reducing
isseminated forms of the disease including TB meningitis [6,7]. In
ddition to the poor efﬁcacy of the current vaccine, a major concern
f its use in countries where TB and HIV are both epidemic, is the
ncreasing risk of complications including lymphadenitis and dis-
eminated BCG in immunosuppressed infants with HIV co-infection
Abbreviations: TB, tuberculosis; MTB, Mycobacterium tuberculosis; IFN-,
nterferon-gamma; PBMC, peripheral blood mononuclear cells; MSMD, Mendelian
usceptibility to mycobacterial disease; BCG, bacille Calmette–Guerin; LTBI, latent
uberculosis infection.
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/).[8]. There is thus an urgent need for better vaccines; however cur-
rent efforts have been hampered by our inadequate understanding
of the basis of immune protection against TB [9,10].
A paradox in the search for biomarkers of protection against TB is
the fact that all existing markers which detect an immune response
to mycobacteria are unable to distinguish between a “successful”
host immune response which results in long term immunity to TB,
and the state of latency which may  progress over time to active
disease [11,12]. For example interferon-gamma (IFN-) response
assays, which detect T cell reactivity to a range of mycobacterial
antigens, are positive in both active disease and latent TB infection
(LTBI) [13]. In the absence of a reliable marker of protective immu-
nity, the selection of candidate vaccines or mycobacterial antigens
for inclusion in new vaccines has relied on animal experiments
which may  not reﬂect immunity to MTB  in man  [14]. In the absence
of biomarkers of protective immunity, large scale Phase III efﬁcacy
studies are the only means of evaluating new vaccines which are
both costly and time consuming.
The introduction of genome wide RNA expression proﬁling has
provided a powerful new method to interrogate the host response
to mycobacteria [15–20]. In this article we  review how RNA expres-
sion proﬁling might provide clues to the nature of protective
immunity against MTB, and how it might be used be used to iden-
tify novel biomarkers of protective immunity that might be used in
subsequent evaluation of novel vaccine candidates.
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Fig. 1. Potential comparisons through which RNA expression data might inform
understanding of host responses to MTB  infection. Comparison between infection
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2nd no disease (A) after exposure might reveal immune mechanisms underlying
usceptibility and resistance. Comparison between disease and no disease after
nfection (B) might indicate pathways required to contain infection.
. How to detect protective immunity to MTB
The growing number of published studies in which genome
ide RNA expression proﬁling has been undertaken in the context
f mycobacterial infection provides a vast amount of new data on
he genomic response to TB [15,18,19,21,22]. However the major
uestion is how to use this data to improve understanding of the
asis of protective immunity. Ideally identiﬁcation of a host RNA
xpression signature of the “protective” immune response would
equire prospective studies and long term follow up of individ-
als exposed to MTB, with comparison ﬁrstly of RNA expression in
hose individuals who remain uninfected (despite exposure) with
hose who develop disease (this would identify a disease suscep-
ible/resistant response) and secondly comparison of those who
nce infected, remain with LTBI lifelong, with those who develop
ctive disease (this would identify the immune response required
o contain infection) (Fig. 1). However, in view of the low rate of pro-
ression to active disease and the relatively small numbers of those
ho after exposure develop TB disease, such studies require fol-
owing up large numbers of patients for many years; nevertheless
hese are being undertaken. As an alternative approach, we  pro-
ose that the nature of the protective transcriptomic response to
ycobacteria might be identiﬁed by studying the following patient
roups:
. Patients with speciﬁc inherited or acquired immune defects that
predispose to mycobacterial infection.
The discovery of Mendelian single gene defects in the IFN-
and IL-12 pathway that confer greatly increased risk of pro-
gressive mycobacterial disease, has implicated a number of
immunological active molecules and pathways that appear to
be essential for containment of mycobacteria [23,24]. The iden-
tiﬁcation of acquired defects in the IFN- response pathway
due to auto-antibodies against IFN-, similarly provides a clue
to the immune pathways essential for successful containment
of mycobacteria [25]. Studies of the transcriptomic differences
between healthy individuals, and those with defects in the IFN-
/IL-12 pathway might identify transcriptomic responses that
are essential for protective immunity to MTB.
. Comparison of the failed and successful immune response to
mycobacteria.3 (2015) 5289–5293
Patients with active TB can be considered as being unable
to contain mycobacterial infection. In contrast, healthy individ-
uals with LTBI are able to successfully contain mycobacterial
infection at least for the time that they remain free of disease.
Comparison of the transcriptome of healthy uninfected individ-
uals, with that of active disease, or LTBI might provide clues to
what constitutes a protective host response to TB.
3. Comparison of highly exposed individuals who  remain life long
without evidence of LTBI, those with long-term latency who  do
not progress to disease and those with LTBI who develop active
disease.
These three groups of patients may  be highly informative as to
the nature of the protective immune response and the speciﬁc
transcriptomic response that distinguishes resistance to infec-
tion, and resistance to development of disease either short or
long term.
By studying these patient groups we will illustrate the poten-
tial of the recently available transcriptomic data to be applied to
addressing these questions.
3. Identifying transcriptomic responses in patients with
inherited or acquired mycobacterial susceptibility defects
Mendelian susceptibility to mycobacterial disease (MSMD) is
an inherited disorder characterised by predisposition to clinical
disease caused by weakly virulent mycobacteria such as poorly
pathogenic strains (non-tuberculous mycobacteria) and Mycobac-
terium bovis BCG (vaccine strains) [26]. Patients are also more
susceptible to salmonellosis, candidiasis and TB [24]. In 1996, our
group and that of Casanova reported mutations in the gene encod-
ing the IFN- receptor, leading to absence of the IFN- receptor 1
chain as a cause of mycobacterial susceptibility [27,28]. Mutations
in seven autosomal (IFNGR1, IFNGR2, IL12B, IL12RB1, STAT1, IRF8,
ISG15) and two  X-linked (NEMO, CYBB) genes have since been iden-
tiﬁed in patients with MSDM [29–33], which all result in impaired
IFN- mediated immunity to infection [23]. However those patients
with defects particularly in the IFNGR1 [34] and IL-12p40 [35]
are found to be particularly susceptible to mycobacterial infec-
tion, including MTB  [23]. These reports collectively demonstrate
that up-regulation of macrophage mycobactericidal mechanisms
through the IFN-/IL-12 pathway is critical for a successful immune
response to mycobacteria.
In 2005, we  reported 3 patients with severe, unexplained,
non-tuberculous mycobacterial infection [25]. We  isolated an
anti-IFN- antibody from the patients’ plasma and showed that
the antibody was functional in (a) blocking the up-regulation
of TNF-alpha production in response to endotoxin, (b) inhibi-
ting transcription of the IFN- inducible genes and (c) inhibiting
up-regulation of HLA class II expression on peripheral blood
mononuclear cells (PBMCs). This report highlighted that predis-
position to mycobacterial susceptibility can be a result of acquired
defects in macrophage activation by IFN-, in addition to genetic
defects in the IFN-/IL-12 pathway [25], and many other patients
with acquired IFN- pathway defects due to auto-antibodies have
now been reported [36–38].
To further explore the immunological consequences of impair-
ment of the IFN- response pathway by anti-IFN- antibodies, we
analysed the transcriptomic response of PBMCs from a healthy
donor stimulated with IFN- in the presence or absence of the
puriﬁed IFN- antibody [25]. Sixty four genes were found to
be signiﬁcantly differentially under-expressed in the presence of
the puriﬁed IFN- antibody [25], and these might be considered
potential biomarkers of the “susceptible” interferon response, and
indicative of the key biological pathways required for protection
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Fig. 2. Biological pathways impaired in the presence of puriﬁed anti-IFN- antibody from a patient with acquired susceptibility to TB. 64 genes, under expressed in the
presence  of an anti-IFN- antibody [25], were assigned to biological pathways using Ingenuity pathway analysis (IPA®). Only genes showing 2.5 fold difference between
control  (no antibody) and treated cells (anti-IFN- antibody) were considered to be under-expressed. Top 12 pathways are shown and ranked by signiﬁcance. Only entities
that  have a −log (p-value) of greater than 4 are displayed. Orange points connected by a thin line represent the ratio of signiﬁcantly differentially expressed genes in each
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o  the web version of this article.)
gainst mycobacteria. When these genes were assigned to biologi-
al pathways using Ingenuity pathway analysis software, we  found
mpairment of multiple pathways in addition to those known to
e involved in interferon signalling, including pathways such as
AK/STAT signalling, crosstalk between dendritic cells and NK cells,
M-CSF signalling, IL-12 signalling and production in macrophages
r T-helper cell differentiation (Fig. 2).
The genes and pathways showing impaired induction in the
resence of anti-IFN- antibodies may  provide clues as to what
istinguishes the protective and susceptible genomic response to
ycobacterial infection. Such comparisons between existing and
ew transcriptomic datasets may  thus yield insight into the genes
nd biological pathways that are essential for protection against
ycobacteria.
. Type I and type II interferon balance – a key to protection
gainst TB?
Identiﬁcation of how the “failed” transcriptomic response in
atients with active TB, differs from the “successful” response in
ealthy individuals with LTBI, might provide important clues to
he nature of the protective immune response. We  focused on type
 (, ) and type II () IFNs that have increasingly been implicated
n mycobacterial immunity.
Although both types of interferon are important in activating the
ost immune response, IFN- is a potent activator of macrophage
ycobactericidal mechanisms, and its essential role in protective
mmunity to mycobacteria has been deﬁnitively established by the
dentiﬁcation of the human gene defects in the IFN- pathway as
iscussed above. In contrast, the role of the type I IFNs in facilitat-
ng mycobacterial growth has been recognised recently. In several
tudies in both mice and humans, overproduction of type I IFNs
as been associated with exacerbation of TB [15,19,39], and the
ranscriptomic signature of active TB has been reported to be char-
cterised by an excess of type I IFNs [19,21,39]. Ottenhoff et al.
15] elucidated a predominant type I IFN mediated transcriptio-
al signature in patients with active TB disease that normalised
uring treatment coincident with up-regulation of IFN-. As a con-
equence of these ﬁndings, type I IFNs and their signalling cascade
ave been proposed as potential quantitative tools for monitoringterpretation of the references to colour in this ﬁgure legend, the reader is referred
active TB [15]. Type I IFNs act to increase production of immune-
suppressive IL-10 and block the responsiveness to IFN- and, as
a consequence, IL-12 production in an IL-27 independent manner
[39]. IL-10 plays a key role in this regulatory system. Suppression
of TNF- and IL-1-production has also been attributed to type I
IFNs.
Mayer-Barber et al. have recently suggested a complex interplay
of interleukin-1 (IL-1), type I IFNs and eicosanoids in controlling
intracellular growth of MTB  [40]. They showed that IL-1 confers
host resistance to MTB  through the induction of eicosanoids that
limit excessive type I IFN production and reduce growth of MTB.
Reduced IL-1 responses and/or excessive type I IFN induction were
shown to be linked to an eicosanoid imbalance associated with dis-
ease exacerbation. In LTBI there appears to be a balance between
IL-1 and type I IFNs, in part mediated by prostaglandin E2, which
prevents uncontrolled inﬂammation. If this balance is disturbed (as
appears to be the case in patients with TB), unopposed activity of
type I IFNs occurs which further suppresses the secretion of IL-
1 and IL-1 mediated by the activity of IL-10 and IL-1 receptor
antagonist [41]. This in turn blocks the production of PGE2 and
the enzyme cyclooxygenase-2 (COX-2). This data suggests that the
inﬂammatory cycle driven by type I IFNs is enhanced in active TB,
promoting mycobacterial growth.
However, the model in which type I IFNs are seen as “bad” and
type II IFNs “good” for containment of MTB, has largely been based
on murine and cellular experiments, and may  not reﬂect the situa-
tion in human TB. The availability of RNA transcriptome data from
patients with active TB and LTBI provides a new way of exploring
the balance between type I IFNs and IFN- in patients with active TB
disease. In order to establish the relative expression of genes that
are controlled by different IFN types in TB patients, we  identiﬁed
the genes that are up- or down-regulated in response to stimulation
of PBMCs with speciﬁc IFNs using the data of Waddell et al. [18]. In
this study genes that are up-regulated or down-regulated in healthy
individuals upon in vitro stimulation of PBMCs with IFN-, IFN-
and IFN- are identiﬁed and reported. We  then explored the over-
lap of IFN-, IFN- and IFN- inducible genes amongst all the genes
that were signiﬁcantly differentially expressed (SDE) between TB
patients and healthy individuals with LTBI (HIV uninfected) using
our published RNA expression data [42].
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Fig. 3. Percentages of up or down regulated genes, that are differentially expressed
in  TB versus LTBI, amongst IFN (, , ) inducible genes. In the study of Waddell et al.
[18], 226, 370 and 111 genes were identiﬁed by microarray analysis as being induced
in  PBMCs stimulated with IFN-, IFN- and IFN- respectively. Of these, 225, 367 and
111  genes (IFN-, IFN- and IFN- respectively) were present in the microarrays
used in the study by Kaforou et al. [42]; 124 (55.1%), 206 (56.3%) and 65 (58.6%)
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[11] Chegou NN, et al. Beyond the IFN-gamma horizon: biomarkers for immun-
odiagnosis of infection with Mycobacterium tuberculosis. Eur Respir Jf these were detected as being signiﬁcantly differentially expressed (adjusted p
alue < 0.05) between TB patients and LTBI individuals with 80.7%, 74.7% and 84.6%
lassiﬁed as up-regulated and 19.3%, 25.3%, 15.4% as down regulated.
As shown in Fig. 3, patients with active TB show up-regulation
f a high proportion of the genes induced by both type I IFNs and
FN-. A surprising ﬁnding from this analysis is that patients with
ctive TB show up regulation of both type I IFN and IFN- induced
enes; we did not observe an “imbalance” between genes induced
y type I IFNs or IFN- (excessive type I IFN production and reduced
FN- production) as we may  have expected. Our analysis suggests
hat active TB occurs in the presence of a robust IFN- response,
s well as an active type I IFN response, and does not support the
implistic view of disease occurring in the context of excess type
 IFNs and defective IFN- responses. A major question for future
tudies is why an apparently robust IFN- response is ineffectual
n containing the infection.
. Identifying “protective” transcriptomic responses: is
L-32 a biomarker of the protective immune response?
In a novel approach to identifying “protective” transcriptional
esponses to TB, a recent publication linked both in vitro data of
he transcriptional response in macrophages and published in vivo
ranscriptome studies [43]. The authors studied RNA expression in
uman macrophages infected with MTB  and used network analysis
f the expressed genes to identify a set of interconnected genes that
orresponded with a network of IL-15 induced defence-response
enes. The hub gene in this network was IL-32 which was shown to
e adequate alone to induce expression of antimicrobial peptides
uch as cathelicidin and DEFB4, at levels comparable with stimula-
ion by IFN- or IL-15. They also showed that IL-32 is a functional
ediator of IFN- induced human macrophage mycobactericidal
ctivity.
In order to identify molecular markers of host defence, Mon-
oya et al. examined the overlap between the gene set induced
y IL-15 and IL-32 in vitro, and those expressed in vivo [43]. The
uthors hypothesised that genes up-regulated in both LTBI and
ealthy uninfected individuals are involved in maintaining MTB
n a dormant state and prevent transition to active disease. They
mployed pairwise comparisons of gene expression in ﬁve pub-
ished clinical data sets [19,42,44,45] of LTBI versus active TB, two
ata sets comparing LTBI versus healthy controls [19,44] and one
ataset including patients with active TB undergoing chemother-
py [45]. This analysis identiﬁed eight genes (also members of
[
[3 (2015) 5289–5293
the IL-15 induced gene set) that were signiﬁcantly up-regulated
in LTBI versus active TB and LTBI versus healthy controls, with vary-
ing degrees of agreement between datasets. However, IL-32 was
the only gene up-regulated in all data sets. Based on this analysis, it
was concluded that IL-32 might serve as a molecular marker of LTBI
and may  be a mediator of the “protective” immune response that
successfully contains MTB  in the latent state. This exciting analysis
demonstrates the power of RNA transcriptomic analysis to reveal
new biological insights, and warrants conﬁrmation in prospective
studies.
6. Conclusions
We  have presented a number of examples of how published
genome wide RNA expression data, derived from microarray stud-
ies of both in vitro and in vivo mycobacterial infection can be used
to identify and characterise the “protective” immune response.
Although we  have focused on IFN induced genes, and the recently
identiﬁed IL-32 pathway, these are only initial examples of how
transcriptomic studies can be interrogated to understand the basis
of protection against MTB  and other mycobacteria. Future studies
linking carefully phenotyped patient groups, monitored over time,
with transcriptomic and genetic analysis, are likely to help reveal
the basis of immune protection against TB and thus make selec-
tion and evaluation of new vaccines possible on a more rational
basis. While RNA expression can provide clues to the overall pat-
tern of gene activation or repression in different clinical responses
to TB, proof that any given pattern of RNA expression will be “pro-
tective” if induced by a candidate vaccine, will ultimately require
veriﬁcation in future clinical studies.
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